Brett Sandercock Sells 1,000 Shares of ResMed Inc. (NYSE:RMD) Stock

ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $233.47, for a total transaction of $233,470.00. Following the completion of the transaction, the chief financial officer now owns 95,812 shares of the company’s stock, valued at approximately $22,369,227.64. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Brett Sandercock also recently made the following trade(s):

• On Monday, September 9th, Brett Sandercock sold 1,000 shares of ResMed stock. The stock was sold at an average price of $246.42, for a total value of $246,420.00.
• On Thursday, August 8th, Brett Sandercock sold 1,000 shares of ResMed stock. The shares were sold at an average price of $212.16, for a total value of $212,160.00.

ResMed Stock Up 0.4 %

RMD traded up $0.98 on Wednesday, hitting $237.04. The company had a trading volume of 749,119 shares, compared to its average volume of 1,042,318. The stock has a market capitalization of $34.82 billion, a price-to-earnings ratio of 36.41, a P/E/G ratio of 2.16 and a beta of 0.69. The stock has a fifty day moving average price of $235.07 and a 200-day moving average price of $213.68. ResMed Inc. has a 12-month low of $132.24 and a 12-month high of $255.18. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.69 and a current ratio of 2.59.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $2.08 EPS for the quarter, topping the consensus estimate of $2.03 by $0.05. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the previous year, the business posted $1.60 EPS. ResMed’s revenue was up 6.9% on a year-over-year basis. Analysts predict that ResMed Inc. will post 9.02 EPS for the current fiscal year.

ResMed Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 19th. Stockholders of record on Thursday, August 15th were given a $0.53 dividend. This is a boost from ResMed’s previous quarterly dividend of $0.48. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.89%. ResMed’s dividend payout ratio (DPR) is presently 32.57%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on RMD shares. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a report on Tuesday, October 1st. Baird R W upgraded ResMed to a “strong-buy” rating in a research report on Tuesday, September 24th. Wolfe Research reaffirmed an “underperform” rating and issued a $180.00 price objective on shares of ResMed in a research note on Wednesday, September 18th. Citigroup lowered ResMed from a “buy” rating to a “neutral” rating in a report on Monday, June 24th. Finally, Oppenheimer lowered shares of ResMed from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, six have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $218.18.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RMD. Elo Mutual Pension Insurance Co grew its position in ResMed by 4.7% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 12,841 shares of the medical equipment provider’s stock worth $2,209,000 after purchasing an additional 573 shares during the last quarter. Neuberger Berman Group LLC increased its position in shares of ResMed by 23.4% in the 4th quarter. Neuberger Berman Group LLC now owns 7,370 shares of the medical equipment provider’s stock valued at $1,268,000 after acquiring an additional 1,399 shares during the period. Vista Investment Management increased its position in shares of ResMed by 4.9% in the 4th quarter. Vista Investment Management now owns 5,347 shares of the medical equipment provider’s stock valued at $920,000 after acquiring an additional 252 shares during the period. Bridgefront Capital LLC purchased a new position in ResMed in the 4th quarter worth $597,000. Finally, Greenvale Capital LLP lifted its position in ResMed by 198.3% during the 4th quarter. Greenvale Capital LLP now owns 551,901 shares of the medical equipment provider’s stock worth $94,938,000 after acquiring an additional 366,901 shares during the period. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.